Health and Prostate

Benign Prostatic Hyperplasia – Prostate Cancer – Prostatitis
RSS

Posts Tagged ‘Phenytoin’

Benign Prostatic Hyperplasia

Posted by admin on July 11th, 2011 No Comments
Definition Benign prostatic hyperplasia, a nearly ubiquitous condition, is the most common benign neoplasm of American men and occurs as a result of hormone-driven prostate growth. Pathophysiology The prostate gland comprises three types of tissue: epithelial or glandular, stromal or smooth muscle, and capsule. Both stromal tissue and capsule are embedded with О±1-adrenergic receptors. The precise pathophysiologic mechanisms that cause Benign prostatic hyperplasia are not clear. However, both intraprostatic dihydrotestosterone and type II 5 О±-reductase are thought to be involved. Benign prostatic hyperplasia commonly results from both static (gradual enlargement of the prostate) and dynamic (agents or situations that increase О±-adrenergic tone and constrict the gland's smooth muscle) factors. Examples of drugs that can exacerbate symptoms include testosterone, О±-adrenergic agonists (e.g., decongestants), anticholinergics (e.g., antihistamines, phenothiazines, tricyclic antidepressants, anticholinergic antispasmodics, Read more [...]
Posted in Benign Prostatic Hyperplasia

Leuprolide Acetate: Cautions

Posted by admin on June 24th, 2011 No Comments
Leuprolide generally is well tolerated and usual dosages (i.e., 1 mg daily) have been associated with fewer adverse systemic effects than usual dosages (i.e., 3 mg daily) of diethylstilbestrol (DES) (no longer commercially available in the US). The most frequent adverse effects associated with leuprolide therapy are hot flushes in males and females and amenorrhea in females. (See Cautions: Endocrine Effects.) These and other effects secondary to hypoestrogenism are the predominant adverse effects observed in females receiving the drug. The safety profiles of the injection and suspension dosage forms of the drug appear to be similar. A worsening (flare) of signs and/or symptoms of hormone-dependent disease (e.g., endometriosis, prostatic carcinoma) has occasionally occurred during the initial 1-2 weeks of leuprolide therapy (secondary to the initial leuprolide-induced stimulation of pituitary release of gonadotropins and resultant ovarian and testicular steroidogenesis) and then subsided during continued therapy. In males with prostate cancer, this transient exacerbation of signs and/or symptoms Read more [...]
Posted in Drugs

Progesterone

Posted by admin on August 9th, 2010 No Comments
(British Approved Name, rINN) Drug Nomenclature International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish): Synonyms: Corpus Luteum Hormone; Luteal Hormone; Luteine; Luteohormone; NSC-9704; Pregnenedione; Progesteron; Progesterona; Progesteronas; Progesteroni; Progesteronum; Progeszteron BAN: Progesterone INN: Progesterone [rINN (en)] INN: Progesterona [rINN (es)] INN: Progestérone [rINN (fr)] INN: Progesteronum [rINN (la)] INN: Прогестерон [rINN (ru)] Chemical name: Pregn-4-ene-3,20-dione Molecular formula: C21H30O2 =314.5 CAS: 57-83-0 ATC code: G03DA04 Read code: y07kn; y07ko Pharmacopoeias. In China, Europe, International, Japan, US. European Pharmacopoeia, 6th ed. (Progesterone). Awhite or almost white crystalline powder or colourless crystals. It exhibits polymorphism. Practically insoluble in water freely soluble in dehydrated alcohol sparingly soluble in acetone and in fatty oils. Protect from light. The United States Pharmacopeia 31, 2008 (Progesterone). A white or creamy-white, odourless, crystalline powder. Practically Read more [...]
Posted in Drugs

The management of benign prostatic hyperplasia: Pharmacotherapy

Posted by admin on December 21st, 2009 No Comments
Recent developments in drug therapy have reduced the number of surgical procedures needed, although in men with severe symptoms, medications may delay but not prevent the need for surgery. Pharmacotherapy has been shown to result in clinically significant subjective improvement in symptoms with fewer side effects and is a viable initial option for all men. Alpha-blockers and 5-alpha-reductase inhibitors comprise the two classes of drugs used to treat benign prostatic hyperplasia (BPH). Table 2 summarizes the pharmacokinetics, dosing, and availability of the alpha-blockers and 5-alpha-reductase inhibitors for the management of BPH. Table 2. Pharmacokinetics, Dosing and Availability of Agents Used in BPH Therapy Nonselective Alpha-Blockers Selective Alpha1A-Blockers 5-alpha-Reductase Inhibitors Doxazosin (Cardura) Pfizer Terazosin (Hytrin) Abbott Prazosin (Minipress) Pfizer Tamsulosin (Flomax) Boehringer Ingelheim Alfuzosin (Xatral) Sanofi- Synthelabo Finasteride (Proscar) Merck Dutasteride (Avodart) GSK Pharma-cokinetics tmax 1-2 Read more [...]
Posted in Benign Prostatic Hyperplasia

Powered by WordPress | Log in | Entries (RSS) | Comments (RSS) | ilookgood! theme by iwritealot!